Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome

References

• Ueland PM, Refsum H, Brattstrøm L. Plasma homocysteine and cardiovascular disease. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function, RB Francis, Jr. Marcel Dekker, Inc, New York 1992; 183–236
   Google Scholar
• Malinow M. Homocyst(e) in and arterial occlusive disease. J Int Med 1994; 236: 603–17
   PubMed Web of Science ®Google Scholar
• Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000; 71: 962–8
   PubMed Web of Science ®Google Scholar
• Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999; 20: 519–29
   PubMed Web of Science ®Google Scholar
• Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17: 459–69
   PubMed Web of Science ®Google Scholar
• Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000; 74: 1196–9
   PubMed Web of Science ®Google Scholar
• Lindblad B, Zaman S, Malik A, Martin H, Ekstrom AM, Amu S, et al. Folate, vitamin B12, and homocysteine levels in South Asian women with growth-retarded fetuses. Acta Obstet Gynecol Scand 2005; 84: 1055–61
   PubMed Web of Science ®Google Scholar
• D'Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand 2004; 83: 155–8
   PubMed Web of Science ®Google Scholar
• Vanderjagt DJ, Patel RJ, El-Nafaty AU, Melah GS, Crossey MJ, Glew RH. High-density lipoprotein and homocysteine levels correlate inversely in preeclamptic women in northern Nigeria. Acta Obstet Gynecol Scand 2004; 83: 536–42
   PubMed Web of Science ®Google Scholar
• Ayar A, Celik H, Ozcelik O, Kelestimur H. Homocysteine-induced enhancement of spontaneous contractions of myometrium isolated from pregnant women. Acta Obstet Gynecol Scand 2003; 82: 789–93
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–7
   PubMed Web of Science ®Google Scholar
• Kilic-Okman T, Guldiken S, Kucuk M. Relationship between Homocysteine and Insulin Resistance in Women with Polycystic Ovary Syndrome. Endocr J 2004; 51: 505–8
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160–5
   PubMed Web of Science ®Google Scholar
• Orio F, Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 673–9
   PubMed Web of Science ®Google Scholar
• Morgante G, La Marca A, Setacci F, Setacci C, Petraglia F, De Leo V. The cardiovascular risk factor homocysteine is not elevated in young women with hyperandrogenism or hypoestrogenism. Gynecol Obstet Invest 2002; 53: 200–3
   PubMed Web of Science ®Google Scholar
• Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA, Tucker MJ. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001; 27: 163–8
   PubMed Web of Science ®Google Scholar
• Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58: 151–4
   PubMed Web of Science ®Google Scholar
• Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90: 2545–9
   PubMed Web of Science ®Google Scholar
• Futterweit W, Dronova L, Tomer Y, Siegel S. Pre-analytical errors: everything that happens to the specimen up to the point of testing. Fertil Steril 2002; 77: 855–6
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clin Endocrinol (Oxf) 2004; 60: 560–7
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Tallova J, Bicikova M, Dvorakova K, Hill M, Starka L. Plasma thiols and androgen levels in polycystic ovary syndrome. Clin Chem Lab Med 2003; 41: 216–21
   PubMed Web of Science ®Google Scholar
• Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003; 18: 721–7
   PubMed Web of Science ®Google Scholar
• Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002; 53: 157–62
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001; 76: 511–6
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005; 20: 3333–40
   PubMed Web of Science ®Google Scholar
• Bayraktar F, Dereli D, Ozgen AG, Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004; 51: 601–8
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Biri A, Bukan N, Karakoc A, Sancak B, Toruner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258–63
   PubMed Web of Science ®Google Scholar
• Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002; 53: 157–62
   PubMed Web of Science ®Google Scholar
• Kilic-Okman T, Guldiken S, Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. Endocr J 2004; 51: 505–8
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951–3
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57: 521–7
   PubMed Web of Science ®Google Scholar
• Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?. J Intern Med 1997; 242: 389–94
   PubMed Web of Science ®Google Scholar
• Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254: 455–63
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002; 110: 74–6
   PubMed Web of Science ®Google Scholar
• Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005; 20: 894–9
   PubMed Web of Science ®Google Scholar
• Kilicdag EB, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, et al. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 2005; 20: 1521–8
   PubMed Web of Science ®Google Scholar
• Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998; 244: 169–74
   PubMed Web of Science ®Google Scholar
• Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19: 1734–40
   PubMed Web of Science ®Google Scholar
• Kjøtrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod 2004; 19: 1315–22
   PubMed Web of Science ®Google Scholar
• von Ahsen N, Schutz E, Armstrong VW, Oellerich M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. Clin Chem 1999; 45: 694–6
   PubMed Web of Science ®Google Scholar
• Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4496–501
   PubMed Web of Science ®Google Scholar